Browsing by Subject "INR"

Sort by: Order: Results:

Now showing items 1-3 of 3
  • Tirri, Tomi (Helsingin yliopisto, 2017)
    Kuvantamista hyödyntävässä toimenpiteessä eli toimenpideradiologiassa on kliininen tarve määrittää potilaan tukos- tai vuototaipumusta. Ultraäänitoimenpiteissä vuotoriskiä ennakoidaan protrombiiniajan (PT) ja siitä johdetun International Ration (INR) avulla. Sydänpotilailla tukosriskiä pienennetään toimenpiteen aikana annostelemalla suonen- sisäisesti hepariinia, jolloin aktivoidulla hyytymisajalla (ACT) voidaan seurata hepariinin vaikutusta. Kannettavalla vierilaitteella voidaan verianalyysit suorittaa toimenpide- huoneessa,jolloin tulosviive pienenee. Tutkielmassa verifioitiin HUS-Kuvantamisen radiologian hankkima ITC Hemochron® Signature Elite-vierilaitteen kokoverianalyysit PT, INR ja aktivoitu partielli tromboplastiiniaika (APTT) vertaamalla laitteen antamia tuloksia laboratorion veriplasmaa käyttäviin analyysituloksiin. Laitteen aktivoidun hyytymisajan (ACT LR ja ACT+) tuloksia verrattiin laboratorion antifaktori X-aktiivisuuteen (anti-FXa). Tavoitteena oli selvittää potilasaineiston avulla soveltuuko ITC Hemochron® Signature Elite-vierilaite kliiniseen käyttöön toimenpideradiologiassa. Ultraäänitoimenpiteissä potilaita oli yhteensä 20 ja sydänpotilaita oli 15. Potilaita ei valikoitu vaan kaikki näyt- teiden keräyspäivinä tammikuussa ja huhtikuussa 2015 HUS-Kuvantaminen radiolo- giassa ulträäni- tai sydäntoimenpiteissä olleet potilaat otettiin mukaan. PT-mittauksissa ero laboratorion menetelmän ja Hemochron® Signature Elite PT:n välillä oli -5,5 sekuntia (-26,3 prosenttia) ja keskinäinen riippuvuus eli korrelaatio vähäinen (R=0,02). INR- mittauksissa ero oli 0,15 (15 prosenttia) ja korrelaatio vähäinen (R=0,1). APTT-mittauk- sissa ero oli 8,4 sekuntia (33,9 prosenttia) ja korrelaatio alhainen (R=0,33). ACT LR:lle ja ACT+:lle ei määritelty eroa, koska mittausasteikko eroaa laboratorion antiFXa:n kanssa. ACT LR:lle saatii korrelaatio oli 0,49 ja ja ACT+:lle 0,35.
  • Vuorinen, Anna-Leena; Lehto, Mika; Niemi, Mikko; Harno, Kari; Pajula, Juha; van Gils, Mark; Lahteenmaki, Jaakko (2021)
    Purpose: To assess the association between VKORC1 and CYP2C9 variants and the incidence of adverse drug reactions in warfarin-treated patients in a real-world setting. Materials and Methods: This was a register-based cohort study (PreMed) linking data from Finnish biobanks, national health registries and patient records between January 1st 2007 and June 30th 2018. The inclusion criteria were: 1) >= 18 years of age, 2) CYP2C9 and VKORC1 genotype information available, 3) a diagnosis of a cardiovascular disease, 4) at least one warfarin purchase, 5) regular INR tests. Eligible individuals were divided into two warfarin sensitivity groups; normal responders, and sensitive and highly sensitive responders based on their VKORC1 and CYP2C9 genotypes. The incidences of clinical events were compared between the groups using Cox regression models. Results: The cohort consisted of 2508 participants (45% women, mean age of 69 years), of whom 65% were categorized as normal responders and 35% sensitive or highly sensitive responders. Compared to normal responders, sensitive and highly sensitive responders had fewer INR tests below 2 (median: 33.3% vs 43.8%, 95% CI: - 13.3%, - 10.0%) and more above 3 (median: 18.2% vs 6.7%, 95% Cl: 8.3%, 10.8%). The incidence (per 100 patient-years) of bleeding outcomes was 5.4 for normal responders and 5.6 for the sensitive and highly sensitive responder group (HR=1.03, 95% CI: 0.74, 1.44). The incidence of thromboembolic outcomes was 4.9 and 7.8, respectively (HR=1.48, 95% CI: 1.08, 2.03). Conclusion: In a real-world setting, genetically sensitive and highly sensitive responders to warfarin had more high INR tests and required a lower daily dose of warfarin than normal responders. However, the risk for bleeding events was not increased in sensitive and highly sensitive responders. Interestingly, the risk of thromboembolic outcomes was lower in normal responders compared to the sensitive and highly sensitive responders.
  • Tiili, Paula; Putaala, Jukka; Mehtala, Juha; Khanfir, Houssem; Niiranen, Jussi; Korhonen, Pasi; Raatikainen, Pekka; Lehto, Mika (2019)
    Background: Intracranial hemorrhage (ICH) is a devastating complication of oral anticoagulation. The aim of this study was to describe the spectrum of ICH and to evaluate the association of warfarin control with the risk of ICH in a nationwide cohort of unselected atrial fibrillation (AF) patients. Methods and Results: The FinWAF is a retrospective registry-linkage study. Data were collected from several nationwide Finnish health-care registers and laboratory databases. The primary outcome was any ICH (traumatic or non-traumatic). The quality of warfarin therapy was assessed continuously by calculating the time in therapeutic range in a 60-day window (TTR60). Adjusted Cox proportional hazard models were used. A total of 53,953 patients were included (53% men; mean age, 73 years; mean follow-up, 2.94 years; mean TTR, 63%). In 129,684 patient-years, 1,196 patients had ICH (non-traumatic, 53.5%; traumatic, 43.6%; traumatic subdural, 38.6%); crude annual rate, 0.92%; 95% CI: 0.87-0.98). A lower TTR60 was significantly associated with higher risk of ICH (TTR60 80%; adjusted hazard ratio, 2.16; 95% CI: 1.83-2.54). Other variables independently associated with ICH included age >65 years, previous stroke, male sex, low hemoglobin, thrombocytopenia, elevated alanine aminotransferase, and previous bleeding other than ICH. Conclusions: Poor control of warfarin treatment was associated with elevated risk of ICH. Approximately half of the ICH were traumatic, mainly subdural.